Physician profile
Jocelyn DO
NPI 1740724962
$4,840.39
in general payments reported to CMS, 2019-2025
18 companies · $1,582 in 2025
The $1,582 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,141 · 2022: $566 · 2023: $615 · 2024: $937 · 2025: $1,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,951 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,950.97 |
| Education | $183.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,509.61 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,012.33 | 2021-2025 | Trulance, Xifaxan |
| Janssen Biotech, INC. | $892.45 | 2021-2025 | Tremfya, Stelara, Simponi |
| Madrigal Pharmaceuticals | $355.84 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $217.62 | 2021 | |
| Gilead Sciences, INC. | $136.12 | 2021-2025 | Epclusa |
| Lilly USA, LLC | $130.54 | 2025 | Omvoh |
| Redhill Biopharma INC. | $98.68 | 2021-2024 | Talicia, Aemcolo, Movantik |
| Celltrion USA INC. | $81.39 | 2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $77.01 | 2025 | Iqirvo |
| Pfizer INC. | $65.53 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $50.48 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $47.47 | 2021-2023 | Linzess |
| Ardelyx, INC. | $43.79 | 2023 | Ibsrela |
| Braintree Laboratories, INC. | $42.39 | 2021-2024 | Suflave, Sutab |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $34.47 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $29.04 | 2025 | Entyvio |
| Albireo Pharma, INC. | $15.63 | 2024 | Bylvay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jocelyn DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.